These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12127874)

  • 1. Telomeres and telomerases as drug targets.
    Rezler EM; Bearss DJ; Hurley LH
    Curr Opin Pharmacol; 2002 Aug; 2(4):415-23. PubMed ID: 12127874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomere inhibition and telomere disruption as processes for drug targeting.
    Rezler EM; Bearss DJ; Hurley LH
    Annu Rev Pharmacol Toxicol; 2003; 43():359-79. PubMed ID: 12540745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase inhibitors: targeting the vulnerable end of cancer?
    Kelland LR
    Anticancer Drugs; 2000 Aug; 11(7):503-13. PubMed ID: 11036953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting telomeres and telomerase.
    De Cian A; Lacroix L; Douarre C; Temime-Smaali N; Trentesaux C; Riou JF; Mergny JL
    Biochimie; 2008 Jan; 90(1):131-55. PubMed ID: 17822826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting human telomerase by antisense oligonucleotides and ribozymes.
    Folini M; Pennati M; Zaffaroni N
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):605-12. PubMed ID: 12678727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to inhibit telomerase activity for cancer therapy.
    Kyo S; Inoue M
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):613-26. PubMed ID: 12678728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures.
    Kim MY; Gleason-Guzman M; Izbicka E; Nishioka D; Hurley LH
    Cancer Res; 2003 Jun; 63(12):3247-56. PubMed ID: 12810655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agents that target telomerase and telomeres.
    Raymond E; Sun D; Chen SF; Windle B; Von Hoff DD
    Curr Opin Biotechnol; 1996 Dec; 7(6):583-91. PubMed ID: 8939642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomeres and telomerase: Pharmacological targets for new anticancer strategies?
    Pendino F; Tarkanyi I; Dudognon C; Hillion J; Lanotte M; Aradi J; Ségal-Bendirdjian E
    Curr Cancer Drug Targets; 2006 Mar; 6(2):147-80. PubMed ID: 16529544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the molecular design of potential anticancer agents via targeting of human telomeric DNA.
    Maji B; Bhattacharya S
    Chem Commun (Camb); 2014 Jun; 50(49):6422-38. PubMed ID: 24695755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Telomere and telomerase as targets for anti-cancer drugs].
    Ide T
    Nihon Rinsho; 2004 Jul; 62(7):1271-6. PubMed ID: 15283143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
    Raymond E; Faivre S; Dieras V; Von Hoff D
    Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function.
    Burger AM; Dai F; Schultes CM; Reszka AP; Moore MJ; Double JA; Neidle S
    Cancer Res; 2005 Feb; 65(4):1489-96. PubMed ID: 15735037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos.
    Izbicka E; Nishioka D; Marcell V; Raymond E; Davidson KK; Lawrence RA; Wheelhouse RT; Hurley LH; Wu RS; Von Hoff DD
    Anticancer Drug Des; 1999 Aug; 14(4):355-65. PubMed ID: 10625928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of human telomerase RNA structure revealed by antisense oligonucleotide technique.
    Vasilkova DV; Azhibek DM; Zatsepin TS; Naraikina YV; Prassolov VS; Prokofjeva MM; Zvereva MI; Rubtsova MP
    Biochimie; 2013 Dec; 95(12):2423-8. PubMed ID: 24035778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide.
    Tarkanyi I; Horváth A; Szatmari I; Eizert H; Vámosi G; Damjanovich S; Ségal-Bendirdjian E; Aradi J
    FEBS Lett; 2005 Feb; 579(6):1411-6. PubMed ID: 15733850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase inhibitors in cancer therapy: current status and future directions.
    Incles CM; Schultes CM; Neidle S
    Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase Inhibitors from Natural Products and Their Anticancer Potential.
    Ganesan K; Xu B
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29267203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase inhibitors.
    Rowley PT; Tabler M
    Anticancer Res; 2000; 20(6B):4419-29. PubMed ID: 11205282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.